Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Interactions between diclofenac and glibenclamide]

K Chlud

    Zeitschrift Fur Rheumatologie
    |September 1, 1976
    PubMed
    Summary
    This summary is machine-generated.

    This study found no significant interaction between Glibenclamid and Diclofenac in diabetic patients. Blood and urine sugar levels remained stable, indicating safety for combined use in well-controlled diabetes.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [Use of topical non-steroidal anti-inflammatory drugs in aggravated and decompensated arthroses].

    Wiener medizinische Wochenschrift (1946)·2000
    Same author

    [Results of efficacy study with diclofenac/orphenadrine infusions in patients with musculoskeletal diseases and functional disorders].

    Acta medica Austriaca·1998
    Same author

    Comparison of tissue and plasma levels of ibuprofen after oral and topical administration.

    Arzneimittel-Forschung·1996
    Same author

    Monitoring of patients with rheumatoid arthritis in longterm administration of D-penicillamine.

    The Journal of rheumatology·1992
    Same author

    [Percutaneous therapy with non-steroidal anti-inflammatory drugs. Pharmacokinetic criteria of effectiveness].

    Fortschritte der Medizin·1991
    Same author

    [Percutaneous therapy of painful arthritis].

    Therapeutische Umschau. Revue therapeutique·1991
    Same journal

    [Prevention strategies in rheumatoid arthritis : From primary prevention to targeted drug interception].

    Zeitschrift fur Rheumatologie·2026
    Same journal

    Methodological concerns and data discrepancies in the indirect treatment comparison of belimumab and anifrolumab.

    Zeitschrift fur Rheumatologie·2026
    Same journal

    Evaluating the comparative efficacy of belimumab vs. anifrolumab in systemic lupus erythematosus: a response.

    Zeitschrift fur Rheumatologie·2026
    Same journal

    [Update: DMARDs for MGUS].

    Zeitschrift fur Rheumatologie·2026
    Same journal

    [A potpourri of diagnoses-Unusual manifestations of a chronic inflammatory bowel disease : Case report].

    Zeitschrift fur Rheumatologie·2026
    Same journal

    [Not measurable but immeasurably important : Fever-The leading symptom of ancient medical theory].

    Zeitschrift fur Rheumatologie·2026
    See all related articles

    Area of Science:

    • Pharmacology
    • Endocrinology
    • Clinical Medicine

    Background:

    • Glibenclamid is a common oral hypoglycemic agent for type 2 diabetes.
    • Diclofenac is a widely used nonsteroidal anti-inflammatory drug (NSAID).
    • Potential drug interactions between Glibenclamid and Diclofenac require investigation.

    Purpose of the Study:

    • To investigate potential interactions between Glibenclamid and Diclofenac.
    • To assess the effect of Diclofenac on glycemic control in patients stabilized on Glibenclamid.

    Main Methods:

    • A randomized, double-blind, placebo-controlled study.
    • 24 diabetic patients on Glibenclamid and a standard diet were enrolled.
    • Patients were randomized to receive either Diclofenac or placebo for 4 days after an initial 3-day observation period.

    Related Experiment Videos

    Main Results:

    • Fasting blood sugar and urine sugar levels were monitored daily.
    • No significant differences in blood or urine sugar were observed between the Diclofenac and placebo groups.
    • Mean blood sugar levels showed no significant changes during the medication period compared to baseline.

    Conclusions:

    • Glibenclamid and Diclofenac do not appear to interact pharmacologically.
    • Diclofenac can likely be safely co-administered with Glibenclamid in well-controlled diabetic patients.
    • Further studies may be warranted to confirm these findings in diverse patient populations.